Group items tagged

Data visualization is one of the most important tools we have to analyze data. But it's just as easy to mislead as it is to educate using charts and graphs. In this article we'll take a look at 3 of the most common ways in which visualizations can be misleading.

When a new drug gets tested, the results of the trials should be published for the rest of the medical world - except much of the time, negative or inconclusive findings go unreported, leaving doctors and researchers in the dark. In this impassioned talk, Ben Goldacre explains why these unreported instances of negative data are especially misleading and dangerous.

Brains are ubiquitous in modern marketing: Headlines proclaim cheese sandwiches help with decision-making, while a "neuro" drink claims to reduce stress. There's just one problem, says neuroscientist Molly Crockett: The benefits of these "neuro-enhancements" are not proven scientifically. In this to-the-point talk, Crockett explains the limits of interpreting neuroscientific data, and why we should all be aware of them.

David Spiegelhalter's background is in medical statistics, particularly the use of Bayesian methods in clinical trials, health technology assessment and drug safety. In his post as Winton Professor for the Public Understanding of Risk he leads a small team (UnderstandingUncertainty.org) that attempts to improve the way in which the quantitative aspects of risk and uncertainty are discussed in society. He gives many presentations to schools and others, advises organisations on risk communication, and is a regular newspaper columnist on current risk issues. He has also appeared on Winter Wipeout. He was elected FRS in 2005 and awarded an OBE in 2006 for services to medical statistics